Literature DB >> 22114136

MicroRNA molecular profiles associated with diagnosis, clinicopathologic criteria, and overall survival in patients with resectable pancreatic ductal adenocarcinoma.

Nigel B Jamieson1, Douglas C Morran, Jennifer P Morton, Asif Ali, Euan J Dickson, C Ross Carter, Owen J Sansom, T R Jeffry Evans, Colin J McKay, Karin A Oien.   

Abstract

PURPOSE: MicroRNAs (miRNA) have potential as diagnostic and prognostic biomarkers and as therapeutic targets in cancer. We sought to establish the relationship between miRNA expression and clinicopathologic parameters, including prognosis, in pancreatic ductal adenocarcinoma (PDAC). EXPERIMENTAL
DESIGN: Global miRNA microarray expression profiling of prospectively collected fresh-frozen PDAC tissue was done on an initial test cohort of 48 patients, who had undergone pancreaticoduodenectomy between 2003 and 2008 at a single institution. We evaluated association with tumor stage, lymph node status, and site of recurrence, in addition to overall survival, using Cox regression multivariate analysis. Validation of selected potentially prognostic miRNAs was done in a separate cohort of 24 patients.
RESULTS: miRNA profiling identified expression signatures associated with PDAC, lymph node involvement, high tumor grade, and 20 miRNAs were associated with overall survival. In the initial cohort of 48 PDAC patients, high expression of miR-21 (HR = 3.22, 95% CI: 1.21-8.58) and reduced expression of miR-34a (HR = 0.15, 95% CI: 0.06-0.37) and miR-30d (HR = 0.30, 95% CI: 0.12-0.79) were associated with poor overall survival following resection independent of clinical covariates. In a further validation set of 24 patients, miR-21 and miR-34a expression again significantly correlated with overall survival (P = 0.031 and P = 0.001).
CONCLUSION: Expression patterns of miRNAs are significantly altered in PDAC. Aberrant expression of a number of miRNAs was independently associated with reduced survival, including overexpression of miR-21 and underexpression of miR-34a.
SUMMARY: miRNA expression profiles for resected PDAC were examined to identify potentially prognostic miRNAs. miRNA microarray analysis identified statistically unique profiles, which could discriminate PDAC from paired nonmalignant pancreatic tissues as well as molecular signatures that differ according to pathologic features. miRNA expression profiles correlated with overall survival of PDAC following resection, indicating that miRNAs provide prognostic utility. ©2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22114136     DOI: 10.1158/1078-0432.CCR-11-0679

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  106 in total

1.  Modeling gene-wise dependencies improves the identification of drug response biomarkers in cancer studies.

Authors:  Olga Nikolova; Russell Moser; Christopher Kemp; Mehmet Gönen; Adam A Margolin
Journal:  Bioinformatics       Date:  2017-05-01       Impact factor: 6.937

2.  Molecular characterization of patient-derived human pancreatic tumor xenograft models for preclinical and translational development of cancer therapeutics.

Authors:  Mike Mattie; Ashley Christensen; Mi Sook Chang; William Yeh; Suzanne Said; Yuriy Shostak; Linnette Capo; Alla Verlinsky; Zili An; Ingrid Joseph; Yi Zhang; Sathish Kumar-Ganesan; Karen Morrison; David Stover; Pia Challita-Eid
Journal:  Neoplasia       Date:  2013-10       Impact factor: 5.715

3.  p85α is a microRNA target and affects chemosensitivity in pancreatic cancer.

Authors:  Paul A Toste; Luyi Li; Brian E Kadera; Andrew H Nguyen; Linh M Tran; Nanping Wu; David L Madnick; Sanjeet G Patel; David W Dawson; Timothy R Donahue
Journal:  J Surg Res       Date:  2015-03-06       Impact factor: 2.192

Review 4.  Long noncoding RNA HOTAIR can serve as a common molecular marker for lymph node metastasis: a meta-analysis.

Authors:  Bin Cai; Zhenjie Wu; Kai Liao; Sen Zhang
Journal:  Tumour Biol       Date:  2014-07-14

5.  Emodin, a natural anthraquinone, suppresses liver cancer in vitro and in vivo by regulating VEGFR2 and miR-34a.

Authors:  Jianguo Bai; Jianfei Wu; Ruifeng Tang; Chao Sun; Junwei Ji; Zhaolin Yin; Guangjun Ma; Wei Yang
Journal:  Invest New Drugs       Date:  2019-04-11       Impact factor: 3.850

Review 6.  Systematic review of peri-operative prognostic biomarkers in pancreatic ductal adenocarcinoma.

Authors:  Wilson Petrushnko; Justin S Gundara; Philip R De Reuver; Greg O'Grady; Jaswinder S Samra; Anubhav Mittal
Journal:  HPB (Oxford)       Date:  2016-07-14       Impact factor: 3.647

7.  Identifying Biomarkers and Drug Targets Using Systems Biology Approaches for Pancreatic Cancer.

Authors:  Yi Tan; Lucio Miele; Fazlul H Sarkar; Zhiwei Wang
Journal:  Pancreat Disord Ther       Date:  2012-12-06

Review 8.  Sweating the small stuff: microRNAs and genetic changes define pancreatic cancer.

Authors:  Siuwah Tang; Jillian Bonaroti; Sebnem Unlu; Xiaoyan Liang; Daolin Tang; Herbert J Zeh; Michael T Lotze
Journal:  Pancreas       Date:  2013-07       Impact factor: 3.327

9.  Long noncoding RNA MALAT1 as a putative biomarker of lymph node metastasis: a meta-analysis.

Authors:  Hui Zhai; Qing-Jie Chen; Bang-Dang Chen; Yi-Ning Yang; Yi-Tong Ma; Xiao-Mei Li; Fen Liu; Zi-Xiang Yu; Yang Xiang; Wu Liao; Hong-Mei Lai
Journal:  Int J Clin Exp Med       Date:  2015-05-15

Review 10.  MicroRNAs as emerging biomarkers and therapeutic targets for pancreatic cancer.

Authors:  Marion Gayral; Sébastien Jo; Naima Hanoun; Alix Vignolle-Vidoni; Hubert Lulka; Yannick Delpu; Aline Meulle; Marlène Dufresne; Marine Humeau; Maël Chalret du Rieu; Barbara Bournet; Janick Sèlves; Rosine Guimbaud; Nicolas Carrère; Louis Buscail; Jérôme Torrisani; Pierre Cordelier
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.